Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ)
CNY43.15
+1.72 (+4.15%)
CN SHZ Healthcare Medical - Instruments & Supplies
Address
No. 68, Lishui Street 110163
Shenyang, CN
Shenyang, CN
CEO
E. Gao
Website
sinqi.com
IPO
2016-12-09
ISIN CNE100002DV1
Description
Shenyang Xingqi Pharmaceutical Co., Ltd, based in Shenyang, China, specializes in the comprehensive process of creating, producing, and distributing ophthalmological products throughout the Chinese market. The company offers a diverse portfolio of eye care solutions, which includes items for corneal health, anti-bacterial applications, artificial tear substitutes, anti-inflammatory medications, surgical perfusion liquids, mydriatic agents, anti-fatigue treatments, and specific therapies for both incipient and severe dry eye conditions.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY43.15
+1.72 (+4.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.25
Float Shares
294.87M
Free Float %
82.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.58% | -11.39% | -19.75% | -23.44% | -22.47% | -20.71% | +6.87% | -19.02% | -6.15% | +1,955.61% | +1,955.61% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
43.15
DCF (Unlevered)
73.92
+71.3%
DCF (Levered)
139.37
+223.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
17.75
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+27.2% ★ Q1'26: +27.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+105.1% ★ Q1'26: +1.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+24.6% ★ Q1'26: +26.6% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+32.5% ★ Q1'26: +33.7% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+41.5% ★ Q1'26: +48.9% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+40.5% Q1'26: +39.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.11× ★ Q1'26: 0.09× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
688.68M
est: 712.30M (-3.3%)
|
688.68M
est: 712.30M (-3.3%)
|
1.03B
est: 1.03B (-0.5%)
|
1.03B
est: 1.03B (-0.5%)
|
1.25B
est: 1.18B (+6.3%)
|
1.25B
est: 1.18B (+6.3%)
|
1.47B
est: 1.48B (-0.9%)
|
1.94B
est: 1.92B (+1.3%)
|
2.47B
est: 2.76B (-10.3%)
|
3.28B
3.28B – 3.28B
+18.9% YoY
|
4.26B
4.26B – 4.26B
+30.0% YoY
|
5.47B
5.47B – 5.47B
+28.4% YoY
|
| EBITDA |
157.61M
est: 177.39M (-11.2%)
|
157.61M
est: 197.64M (-20.3%)
|
297.55M
est: 257.19M (+15.7%)
|
297.55M
est: 286.55M (+3.8%)
|
297.23M
est: 292.85M (+1.5%)
|
297.23M
est: 326.28M (-8.9%)
|
340.30M
est: 410.93M (-17.2%)
|
499.83M
est: 532.19M (-6.1%)
|
917.40M
est: 764.71M (+20.0%)
|
908.99M
908.99M – 908.99M
+18.9% YoY
|
1.18B
1.18B – 1.18B
+30.0% YoY
|
1.52B
1.52B – 1.52B
+28.4% YoY
|
| EBIT |
112.10M
est: 138.02M (-18.8%)
|
112.10M
est: 161.19M (-30.5%)
|
240.31M
est: 200.10M (+20.1%)
|
240.31M
est: 233.70M (+2.8%)
|
231.20M
est: 227.84M (+1.5%)
|
231.20M
est: 266.10M (-13.1%)
|
259.93M
est: 335.14M (-22.4%)
|
408.42M
est: 434.03M (-5.9%)
|
804.71M
est: 623.66M (+29.0%)
|
741.33M
741.33M – 741.33M
+18.9% YoY
|
963.77M
963.77M – 963.77M
+30.0% YoY
|
1.24B
1.24B – 1.24B
+28.4% YoY
|
| Net Income |
87.98M
est: 68.30M (+28.8%)
|
87.98M
est: 66.18M (+32.9%)
|
194.70M
est: 148.95M (+30.7%)
|
194.70M
est: 144.31M (+34.9%)
|
211.68M
est: 184.48M (+14.7%)
|
211.68M
est: 178.74M (+18.4%)
|
240.04M
est: 181.84M (+32.0%)
|
338.06M
est: 263.06M (+28.5%)
|
695.86M
est: 522.72M (+33.1%)
|
648.30M
648.30M – 648.30M
+24.0% YoY
|
896.09M
896.09M – 896.09M
+38.2% YoY
|
1.22B
1.22B – 1.22B
+35.6% YoY
|
| SGA |
320.21M
est: 328.53M (-2.5%)
|
320.21M
est: 288.76M (+10.9%)
|
456.54M
est: 476.32M (-4.2%)
|
456.54M
est: 418.66M (+9.0%)
|
595.39M
est: 542.36M (+9.8%)
|
595.39M
est: 476.69M (+24.9%)
|
689.80M
est: 600.38M (+14.9%)
|
875.78M
est: 777.53M (+12.6%)
|
459.35M
est: 1.12B (-58.9%)
|
1.33B
1.33B – 1.33B
+18.9% YoY
|
1.73B
1.73B – 1.73B
+30.0% YoY
|
2.22B
2.22B – 2.22B
+28.4% YoY
|
| EPS |
0.78
est: 0.39 (+100.0%)
|
0.78
est: 0.27 (+190.0%)
|
1.58
est: 0.85 (+85.8%)
|
1.58
est: 0.59 (+169.4%)
|
1.71
est: 1.05 (+62.4%)
|
1.71
est: 0.73 (+135.4%)
|
1.38
est: 0.74 (+86.8%)
|
1.39
est: 1.07 (+30.0%)
|
2.83
est: 2.12 (+33.2%)
|
2.63
2.63 – 2.63
+24.0% YoY
|
3.64
3.64 – 3.64
+38.2% YoY
|
4.94
4.94 – 4.94
+35.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
790.27M
OE per share TTM
3.22
Owner's Yield
8.37%
Maintenance CapEx ratio
28.23%
Maint CapEx / Avg PPE
57.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 27 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.03% | 5.1K | 0.65% |
| 2 | State Street SPDR S&P China ETF GXC | 0.01% | 62.8K | 0.59% |
| 3 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.8K | 0.15% |
| 4 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 30.1K | 0.49% |
| 5 | Dimensional - Emerging Markets High Profitability ETF DEHP | 0.00% | 18.6K | 0.44% |
| 6 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 216.1K | 0.06% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 83.5K | 0.17% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 83.5K | 0.17% |
| 9 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 8.4K | 0.44% |
| 10 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 124.0K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
331.7K
Shares Outstanding
357.32M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chunhua Li | Director of the Administrative Management Department & Director | — | male |
| E. Gao | MD, GM & Non-Independent Director | — | female |
| Fei Ji | Human Resources Specialist & Employee Representative Supervisor | — | female |
| Qiang Yang | Head of R&D Center, Deputy GM & Director | — | male |
| Shaoyao Zhang | Deputy Chairman, Deputy GM & Secretary of the Board | — | male |
| Xie Min | Head of the Accounting Department & Accounting Supervisor | — | — |
| Yanan Cheng | Deputy GM, Financial Director, Chief Financial Officer & Non-Independent Director | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300573.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
